Micron Biomedical Secures $33M for Needle-Free Vaccine Technology

Micron Biomedical, a clinical-stage life science company, has recently secured additional funding to further its mission of expanding access to vaccines and therapeutics globally. The company, which is developing a proprietary dissolvable microarray technology for needle-free drug delivery, has added $16 million to its Series A equity round, bringing the total to over $33 million.

This funding round was led by J2 Ventures and the Global Health Investment Corporation (GHIC), and it will be used to expand commercial manufacturing for Micron Biomedical’s drug delivery technology. The company’s technology is designed to simplify the delivery of drugs and vaccines by eliminating the need for traditional injections and cold storage. This not only makes the administration process easier but also reduces waste and enhances safety.

Micron Biomedical’s microarray technology has shown promising results in clinical trials. It has been demonstrated to be at least as effective as traditional injections in adults and children as young as nine months old. The technology allows for self-administration or caregiver-administration, making it particularly beneficial in low- and middle-income countries where access to healthcare professionals and refrigeration for vaccine storage can be limited.

The company has received significant recognition and support from various organizations, including a $3.7 million grant from CEPI, $2 million from the BARDA Patch Forward competition, and $7.5 million from the Bill & Melinda Gates Foundation. These funds will be used to support the first Phase 2 clinical trial of Micron Biomedical’s needle-free measles/rubella vaccine.

Micron Biomedical is on a rapid path to commercializing its proprietary technology, which has the potential to be game-changing in humanitarian settings. The company’s focus on improving access to vaccines and therapeutics aligns with global health, regulatory, and commercial leaders’ urgent need for needle-free solutions.

The recent funding will accelerate Micron Biomedical’s ability to bring its technology to more people who either cannot access traditional injections or prefer to receive medications and vaccines without needles. The company’s commitment to improved health outcomes through better access and convenience is underscored by its continued progress in addressing access challenges in global health.

Micron Biomedical’s technology has been recognized for its potential to eradicate diseases by simplifying and improving the transport, storage, and administration of drugs and vaccines. The company’s dissolvable microarray technology is designed to be injection-free, painless, and simple to administer, either by self-administration or caregiver-administration. This technology not only enhances safety and efficacy but also improves patient compliance.

With its state-of-the-art facilities for microneedle formulation, design, and process development, along with cGMP manufacturing capabilities, Micron Biomedical is well-positioned to meet the global demand for its innovative technology. The company’s team of scientists, engineers, and quality professionals brings vast experience in the medical device, biopharmaceutical, and manufacturing fields, further solidifying its position as a leader in the industry.

See more funded startups in USA.